Happy butterscotch pudding day from the wBW team! We’ve put together the freshest news from our good industry.

By Seymur Mammadov in Baku Armenia must adhere to a multi-vector foreign policy while effectively managing risks, as Prime ...

Furthermore, beyond the immediate trial, there is a broader potential for approval and product launches from Rocket’s lentiviral vector-based therapies, which adds to the investment case. The Phase 2 ...

Analyst Cory Jubinville, PhD of LifeSci Capital maintained a Buy rating on Rocket Pharmaceuticals (RCKT – Research Report), retaining the ...

The company said the single-arm multicenter Phase II trial may support accelerated approval for the RP-A501 gene therapy in the US.

Australia and India are expanding their space collaboration, focusing on supporting India's Gaganyaan mission and launching ...

Rocket Pharmaceuticals, Inc. , a fully integrated, late-stage biotechnology company advancing a sustainable pipeline of genetic therapies for rare disorders with high unmet need, today announced that ...